Back

An integrative multimodal machine learning signature of primary resistance to immunotherapy in advanced non-small cell lung cancer: biomarker analysis from the PIONeeR study

2026-01-11 oncology Title + abstract only
View on medRxiv
Show abstract

BackgroundImmune checkpoint inhibitors (ICIs) have transformed the treatment landscape for advanced non-small cell lung cancer (NSCLC), yet primary resistance remains common, with only [~]50% of patients responding to first-line chemo-immunotherapy and 20-30% to monotherapy. Existing biomarkers such as PD-L1 expression and Tumor Mutational Burden (TMB) demonstrate limited predictive accuracy, underscoring the need for more comprehensive, integrative approaches. MethodsWe conducted a prospective...

Predicted journal destinations